Please assess the completion status of the following clinical trial:

Trial Title: A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Heart failure with reduced ejection fraction (LVEF on echocardiogram of 40% or less)~* Stable guideline directed therapy for heart failure including oral diuretics, ACEi, ARBs, ARNi, MRAs, and β blockers as tolerated, with no dose changes of these medications in the past 2 weeks~* Have screening values of NT pro-BNP ≥ 125 pg/mL (15 pmol/L) or BNP ≥ 35 pg/mL (10 pmol/L)~Exclusion Criteria:~* Systolic blood pressure (SBP) \< 110 mm Hg at screening or pre-randomization~* Heart rate \< 50 beats per minute (bpm) or \> 90 bpm at screening or pre-randomization~* Permanent Atrial Fibrillation, Atrial Flutter or having Atrial Fibrillation, Atrial Flutter~* Estimated glomerular filtration rate (eGFR) \< 15 ml/min/1.73 m2~* Ventricular assist device or prior heart transplant~* Prior solid organ transplant~* Body weight \< 45 kg or ≥ 140 kg~* Low quality echocardiographic visualization windows and image acquisition~* Permanent paced rhythm (VVI, DDD or BiV pacing)~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo/BMS-986231/NTG (Type: EXPERIMENTAL): administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
- Placebo/NTG/BMS-986231 (Type: EXPERIMENTAL): administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
- NTG/Placebo/BMS-986231 (Type: EXPERIMENTAL): administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
- NTG/BMS-986231/Placebo (Type: EXPERIMENTAL): administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
- BMS-986231/Placebo/NTG (Type: EXPERIMENTAL): administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
- BMS-986231/NTG/Placebo (Type: EXPERIMENTAL): administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods

Based on this trial design, predict the completion outcome and termination type (if applicable).